Zacks Research Has Pessimistic Outlook of EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Edwards Lifesciences in a note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $0.58 per share for the quarter, down from their previous forecast of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.61 EPS, FY2025 earnings at $2.42 EPS, Q1 2026 earnings at $0.66 EPS, Q2 2026 earnings at $0.69 EPS and FY2026 earnings at $2.78 EPS.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The business’s revenue was up 8.9% on a year-over-year basis.

EW has been the subject of several other research reports. Piper Sandler reduced their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Barclays reduced their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Truist Financial decreased their price objective on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Finally, Wells Fargo & Company decreased their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Trading Up 0.2 %

NYSE:EW opened at $70.49 on Friday. The firm’s 50 day moving average is $67.70 and its 200 day moving average is $75.73. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $41.58 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of EW. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $29,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $32,000. Finally, Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock worth $2,657,000. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.